Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis

Pfizer’s Xeljanz Approved in EU for Adults with Moderate to Severe Ulcerative Colitis
The European Commission has approved Pfizer's Xeljanz (tofacitinib) for the treatment of adults with moderate to severe active ulcerative colitis (UC) who have failed to fully respond to other therapies. The approved regimen is 10 mg of oral Xeljanz twice a day for at least eight weeks, after which patients can continue on the twice-daily therapy, either at 5 mg or 10 mg. Approval in the EU follows that of the U.S. Food and Drug Administration for the same indication. The
Subscribe or to access all post and page content.